Antineoplaston treatment for gliomas granted orphan drug designation by FDA
Government plans to make certain prescription-only drugs for common problems available over the counter have overwhelmingly been given the thumbs down by healthcare professionals, reveals a survey of readers of the influential Drug and Therapeutics Bulletin (DTB). The prevailing view among readers, many of whom are healthcare professionals working in primary care, is that drug
Full Post: Thumbs down by experts on plans to make certain meds OTC
The Burzynski Research Institute, Inc. (BRI) has announced that its antineoplaston A10 and antineoplaston AS2-1 therapy (ANP) has been granted orphan drug designation by the U.S. Food and Drug Administration (”FDA”) for the treatment of gliomas. It is estimated that in 2008 more than 21,000 men and women in the U.S. will be diagnosed with this type of cancer, with prevalence estimated at approximately 84,000 cases.
“We are encouraged by the FDA’s action. Initially, BRI sought orphan drug designation for ANP in optic pathway glioma in children, a much narrower indication involving a smaller segment of tumors,” said Dr. Stanislaw R. Burzynski, M.D., Ph.D. “However, the FDA extended orphan drug designation to all gliomas, a recognition we believe underlies the broad potential of anitneoplaston therapy for the treatment of patients with cancer of the brain and nervous system. There is now even more motivation for us to evaluate our therapy as an innovative and efficacious choice in a treatment spectrum where disease management options are still quite limited.”
Orphan drug designation, as granted by the FDA’s Office of Orphan Products Development, was designed to encourage clinical development of products for use in rare diseases or conditions, usually defined as affecting fewer than 200,000 people in the United States. Orphan drug designation provides an economic incentive that stimulates the development of new products in the oncology field and allows for seven years of market exclusivity upon final FDA approval, as well as clinical study and R&D support, reduction in regulatory fees and potential tax credits.
Research and development efforts are focused on basic ANP research and 19 Phase II clinical trials, some of which are coming now to a successful conclusion. Since ANP effects approximately 100 genes instrumental in the growth of glioblastoma multiforme, the results of research have been and will be presented in a number of neuro-oncology meetings and published as abstracts in Neuro-Oncology. Earlier this year the BRI team presented at the 13th International Symposium of Pediatric Neuro-Oncology in Chicago, Illinois (June 29-July 2, 2008), a successful preliminary report on the phase II study of ANP in children with optic pathway glioma. At the September 2008 annual meeting of the European Association for Neuro-Oncology in Barcelona, Spain, BRI presented two reports. In one of them, it was described how the ingredients of ANP down-regulate energy producing pathways in glioblastoma cells. The second report described preliminary successful results of Phase II study of ANP in patients with recurrent anaplastic astrocytoma. Most recently, BRI presented two additional reports on preliminary results of phase II study of ANP in patients with newly-diagnosed anaplastic astrocytoma and on the affects of ANP’s ingredients on cell cycle checkpoint which lead to apoptosis in human glioblastoma cells at the Society of Neuro-Oncology’s annual meeting in November 2008.
Burzynski Research Institute, Inc. is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles.
Reata Pharmaceuticals, Inc. has announced that RTA 402 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. RTA 402 is currently being studied in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease.
Full Post: FDA grants orphan drug status to Reata’s pancreatic cancer drug
Kiadis Pharma has announced that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc(TM) is under development
Full Post: Kiadis Pharma receives two orphan drug designations for Reviroc
Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today that SQ109, its lead drug candidate for the treatment of tuberculosis (TB), was the first drug approved for evaluation in a newly awarded clinical program contract to Dynport Vaccine Company LLC and Quintiles Transnational. The contract, awarded by the National Institute
Full Post: Sequella, Inc. drug compound SQ109 selected for phase 1B clinical trial program
Savient Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s Biologics License Application (BLA) for pegloticase, a novel biological drug for treatment-failure gout (TFG) patients. The FDA also granted the Company’s BLA with a priority review status which accelerates the review period to six months. A
Full Post: Pegloticase BLA filing accepted for priority review by FDA
Dyax Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) and has designated the application for Priority Review. Based on this designation, the FDA Prescription Drug User Fee Act (PDUFA)
Full Post: FDA accepts filing and grants priority review for DX-88 for hereditary angioedema